

**File No. Blood Centre/Misc-DCC/Advisory/09/2023 -D**  
**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organization**  
**(Blood Centre Division)**

FDA Bhawan, Kotla Road,  
New Delhi-110002  
Dated: 26/12/2023

To

**All State/UTs Drugs Controller cum Licensing Authorities.**

**Sub: Action Taken on the recommendation of 62nd Drugs Consultative Committee meeting-reg.**

Sir/Madam,

This is with reference to the 62nd meeting of the Drugs Consultative Committee held on 26.09.2023 in hybrid mode wherein it was recommended with respect of Agenda No. 18 of ATR point 3, for overcharging of blood, and it was opined that blood is not for sale, it is only for supply and only processing cost may be charged by the blood centre. It was opined to issue an advisory to all blood centres regarding NBTC revised guideline for recovery of processing charges for blood and blood components.

In this regard, you are requested to direct all the Blood Centre under your jurisdiction to adhere with the Revised Guidelines-2022 for Recovery of Processing Charges for Blood and Blood Components issued by NBTC, MoHFW, Nirman Bhawan, New Delhi vide dated 14.06.2022. (copy enclosed)

This is for your information and necessary compliance.

Yours faithfully

  
(Dr. RAJEEV SINGH RAGHUVANSHI)  
DRUGS CONTROLLER GENERAL (INDIA)

Copy for information to:

1. All Zonal/ Sub zonal offices of CDSCO for necessary compliance and coordination with respective State/UTs Licensing Authorities in the matter.